Cordlife Group Limited
Annual Report 2016
117
Notes to
The Financial Statements
for the financial year ended 30 June 2016
40. Segment reporting
For management reporting purposes, the Group monitors the performance of the business units based on their
products and services and has two reportable segments as follows:
The banking segment comprises of cord blood and cord lining services. Cord blood and cord lining are
collected, processed and stored in the various laboratories in the regions that the Group operates in.
The diagnostics segment comprises Metascreen, which is a comprehensive metabolic screening test
specially designed for newborn babies, non-invasive prenatal testing service and Eyescreen, a non-
invasive paediatric eye-screening service.
The following items and associated assets and liabilities are not allocated to operating segments as they are not
considered part of the core operations of any segment:
Interest income excluding interest income on long-term trade receivables.
Income taxes that are managed on a group basis.
Subsidiaries not in the principal activities of the provision of cord blood and cord lining banking services
and metabolic screening.
No operating segments have been aggregated to form the above reportable operating segments.
Segment revenue
Banking
Diagnostics
Others
*
Total
$’000
$’000
$’000
$’000
Year ended 30 June 2016
Revenue from external customers
59,095
532
–
59,627
Total consolidated revenue
59,627
Year ended 30 June 2015
Revenue from external customers
57,436
103
44
57,583
Total consolidated revenue
57,583
*
Others refer to the revenue of subsidiaries not in the principal activities of the provision of cord blood and cord lining
banking and diagnostics services.
